A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease

Nature

Volumn 549, Issue 7672, 2017, Pages 389-393

  Mass, Elvira ^a   Jacome Galarza, Christian E ^a   Blank, Thomas ^b   Lazarov, Tomi ^a   Durham, Benjamin H ^a   Ozkaya, Neval ^a   Pastore, Alessandro ^a   Schwabenland, Marius ^b   Chung, Young Rock ^a   Rosenblum, Marc K ^a   Prinz, Marco ^b   Abdel Wahab, Omar ^a   Geissmann, Frederic ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CASPASE 3; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; B RAF KINASE;

CELLS AND CELL COMPONENTS; DISEASE; GENE EXPRESSION; MUTATION; NERVOUS SYSTEM DISORDER; PHYSIOLOGY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL SELECTION; CELL SUSPENSION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOFLUORESCENCE; KUPFFER CELL; MACROPHAGE; MICROGLIA; MOUSE; MYELOID PROGENITOR CELL; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RNA SEQUENCE; ROTAROD TEST; SOMATIC MUTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CLONE; DISEASE MODEL; ENZYMOLOGY; ERYTHROID PRECURSOR CELL; FEMALE; GENETICS; HISTIOCYTOSIS; MALE; MAPK SIGNALING; METABOLISM; MOSAICISM; MUTATION; PATHOLOGY;

MUS;

ANIMALS; CLONE CELLS; DISEASE MODELS, ANIMAL; ERYTHROID PRECURSOR CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HISTIOCYTOSIS; HUMANS; MACROPHAGES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICROGLIA; MOSAICISM; MUTATION; MYELOID PROGENITOR CELLS; NEURODEGENERATIVE DISEASES; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 85029804432     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23672     Document Type: Article

References (41)

1. Ransohoff, R. M. How neuroinflammation contributes to neurodegeneration. Science 353, 777-783 (2016).
2. Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061-1071 (2015).
3. Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712-716 (2016).
4. Paloneva, J. et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71, 656-662 (2002).
5. Rademakers, R. et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 44, 200-205 (2011).
6. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116 (2013).
7. Guerreiro, R. et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013).
8. Hellwig, S., Heinrich, A. & Biber, K. The brain's best friend: microglial neurotoxicity revisited. Front. Cell. Neurosci. 7, 71 (2013).
9. Lachenal, F. et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J. Neurol. 253, 1267-1277 (2006).
10. Laurencikas, E. et al. Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study. Pediatr. Blood Cancer 56, 250-257 (2011).
11. Wnorowski, M. et al. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J. Pediatr. 153, 127-132 (2008).
12. Rigaud, C. et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br. J. Haematol. 174, 887-898 (2016).
13. Héritier, S. et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J. Clin. Oncol. 34, 3023-3030 (2016).
14. Badalian-Very, G. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116, 1919-1923 (2010).
15. Satoh, T. et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE 7, e33891 (2012).
16. Haroche, J. et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120, 2700-2703 (2012).
17. Diamond, E. L. et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 6, 154-165 (2016).
18. Berres, M. L. et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J. Exp. Med. 211, 669-683 (2014).
19. Chung, S. S. et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci. Transl. Med. 6, 238ra71 (2014).
20. Schulz, C. et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86-90 (2012).
21. Kierdorf, K. et al. Microglia emerge from erythromyeloid precursors via Pu.1-and Irf8-dependent pathways. Nat. Neurosci. 16, 273-280 (2013).
22. Gomez Perdiguero, E. et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547-551 (2015).
23. Mass, E. et al. Specification of tissue-resident macrophages during organogenesis. Science 353, aaf4238 (2016).
24. Behjati, S. et al. Genome sequencing of normal cells reveals developmental lineages and mutational processes. Nature 513, 422-425 (2014).
25. Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880-886 (2015).
26. Mercer, K. et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res. 65, 11493-11500 (2005).
27. Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breasttumour metastasis. Nature 475, 222-225 (2011).
28. Patel, H. C., Boutin, H. & Allan, S. M. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann. NY Acad. Sci. 992, 39-47 (2003).
29. Campbell, I. L. et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl Acad. Sci. USA 90, 10061-10065 (1993).
30. Waisman, A., Hauptmann, J. & Regen, T. The role of IL-17 in CNS diseases. Acta Neuropathol. 129, 625-637 (2015).
31. Caton, M. L., Smith-Raska, M. R. & Reizis, B. Notch-RBP-J signaling controls the homeostasis of CD8? dendritic cells in the spleen. J. Exp. Med. 204, 1653-1664 (2007).
32. Deng, L. et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am. J. Pathol. 176, 952-967 (2010).
33. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008).
34. Guyenet, S. J. et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J. Vis. Exp. (39) 1787 (2010).
35. Bittner, S., Afzali, A. M., Wiendl, H. & Meuth, S. G. Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. J. Vis. Exp. (86) (2014).
36. Carter, R. J. et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19, 3248-3257 (1999).
37. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
38. Patro, R., Mount, S. M. & Kingsford, C. Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nat. Biotechnol. 32, 462-464 (2014).
39. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
40. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284-287 (2012).
41. Diamond, E. L. et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124, 483-492 (2014).